<DOC>
	<DOC>NCT02440633</DOC>
	<brief_summary>To obtain absorption, metabolism and excretion data for parent drug and any metabolites.</brief_summary>
	<brief_title>A Phase 1,Open -Label Study to Assess the Absorption, Metabolism and Excretion of 14C-OPS-2071 Following a Single Oral Dose to Healthy Male Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Enteritis</mesh_term>
	<criteria>Healthy males Body mass index (BMI) between 18.5 and 25.0 kg/m2, inclusive Subjects will have given their written informed consent to participate in the study and to abide by the study restrictions Subjects who have a significant history of alcoholism or drug/chemical abuse, as determined by the Investigator. Subjects who smoke, or who have used nicotine within 3 months prior to screening.. Subjects who have a significant history of drug allergy, as determined by the Investigator. Subjects who have any clinically significant abnormal physical examination finding. Subjects who have any clinically significant medical history, as determined by the Investigator. Subjects who are exposed to radiation as a result of their occupation. Subjects who have had an X ray or CT scan, or who have participated in any trial involving a radiolabelled investigational product or have been exposed to radiolabelled substances within 12 months prior to dose administration.</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>